Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world? Authors' reply

Loomba, Rohit; Wong, Robert J.; Fraysse, Jeremy; Shreay, Sanatan; Li, Suying; Harrison, Stephen A.; Gordon, Stuart C.

doi:10.1111/apt.15724

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, all existing data on epidemiology, natural history, biomarkers, and clinical trials in NAFLD population can be extrapolated to MASLD patients. 13…”

Section: Implication In Clinical Practicementioning

confidence: 99%

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

Canivet,

Boursier,

Loomba

2024

Semin Liver Dis

View full text Add to dashboard Cite

In June 2023, under the patronage of the American Association for Study of Liver Disease, the European Association for Study of the Liver, and the Asociación Latinoamericana para el Estudio del Hígado with the involvement of 236 participants from around the world, a new nomenclature and definition for nonalcoholic fatty liver disease (NAFLD) has been proposed. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined as presence of hepatic steatosis and at least one of the cardiometabolic risk factors with alcohol intake less than 140 g/wk for women and 210 g/wk for men and no other causes of steatosis. A new entity called combined metabolic dysfunction- and alcohol-associated liver disease (MetALD) was created outside of pure MASLD for patients with metabolic dysfunction and alcohol intake greater than that allowed for MASLD (i.e., 140–350 g/wk for women and 210–420 g/wk for men). Recent studies have confirmed a 95% overlap between NAFLD and the new MASLD diagnostic criteria. Natural history, biomarkers, and thresholds of alcohol intake in MetALD group remains to be studied and validated.

show abstract

“…Thus, all existing data on epidemiology, natural history, biomarkers, and clinical trials in NAFLD population can be extrapolated to MASLD patients. 13…”

Section: Implication In Clinical Practicementioning

confidence: 99%

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

Canivet,

Boursier,

Loomba

2024

Semin Liver Dis

View full text Add to dashboard Cite

show abstract

“…1 Metabolic dysfunction-associated steatohepatitis (MASH), wherein steatosis is associated with hepatocyte damage including inflammation, hepatocyte ballooning, and fibrosis, occurs in a subset of approximately 20% individuals with MASLD. 2 3 4 A key challenge in the field stems from the heterogeneous nature of disease progression in MASLD and the noninvasive identification of patients at highest risk of adverse clinical outcomes. Individuals with MASH are at risk for progression to cirrhosis and end-stage liver disease with development of hepatocellular carcinoma (HCC) and need for liver transplantation.…”

Section: Lay Summarymentioning

confidence: 99%

Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis

Tincopa,

Loomba

2024

Semin Liver Dis

View full text Add to dashboard Cite

Risk of disease progression and clinical outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with fibrosis stage and presence of “at-risk metabolic dysfunction-associated steatohepatitis (MASH).” Although liver biopsy is considered the gold standard to diagnose MASH and stage of fibrosis, biopsy is infrequently performed in clinical practice and has associated sampling error, lack of interrater reliability, and risk for procedural complications. Noninvasive tests (NITs) are routinely used in clinical practice for risk stratification of patients with MASLD. Several NITs are being developed for detecting “at-risk MASH” and cirrhosis. Clinical care guidelines apply NITs to identify patients needing subspecialty referral. With recently approved Food and Drug Administration treatment for MASH and additional emerging pharmacotherapy, NITs will identify patients who will most benefit from treatment, monitor treatment response, and assess risk for long-term clinical outcomes. In this review, we examine the performance of NITs to detect “at-risk MASH,” fibrosis stage, response to treatment, and risk of clinical outcomes in MASLD and MASH.

show abstract

Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world? Authors' reply

Abstract: LINKED CONTENT This article is linked to Loomba et al and Harris et al papers. To view these articles, visit https://doi.org/10.1111/apt.15679 and https://doi.org/10.1111/apt.15714.

Cited by 2 publications

References 7 publications

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis

Contact Info

Product

Resources

About